TP53 truncating mutation as a predictive biomarker for induction chemotherapy in patients with locally advanced oral squamous cell carcinoma

doi:10.19438/j.cjoms.2018.04.006

Abstract

Abstract: PURPOSE:To test the status of TP53 mutations in patients with locally advanced oral squamous cell carcinoma (OSCC) and investigate whether or not TP53 truncating mutation could be used as a predictive biomarker to screen patients who would benefit from induction chemotherapy. METHODS: One hundred and one patients with locally advanced OSCC treated in our hospital from 2008 to 2014 were included in this study. Their clinicopathologic information, frozen or formalin-fixed, paraffin-embedded samples of tumor and matched normal samples were collected. Using Ion PGM system, all samples were sequenced with high-throughput technology. Bioinformatics software was used to analyze and interpret the variants. SPSS 23.0 software package was used for statistical analysis. RESULTS: Among 101 patients, there were 74 men and 27 women with a median age of 59 years. The median follow-up time was 34.9 months. There were 102 TP53 non-synonymous mutations (allele frequency ≥3%) in 73 OSCC patients, with an average sequencing depth of 2366-fold in the tumor samples and 2225-fold in the matched normal samples. Compared with 42 patients who did not receive induction chemotherapy, 59 patients who received induction chemotherapy had a seemingly better distant metastasis free survival (P=0.090) while no significant difference in overall survival. Subgroup analysis showed that patients with TP53 truncating mutations could benefit from induction chemotherapy in distant metastasis free survival (P=0.038). CONCLUSIONS: Our study does not find that the patients with locally advanced OSCC could benefit from induction chemotherapy in overall survival, but TP53 truncating mutation could be used as a candidate of predictive biomarker to screen patients who would benefit from induction chemotherapy in distant metastasis free survival.

Key words: Oral squamous cell carcinoma, TP53 truncating mutation, Distant metastasis free survival, Biomarker, Induction chemotherapy

CLC Number:

R739.8

FU Yong, MA Jie, LIU Ying, TAN Yi-ran, JU Wu-tong, SUN Wen-wen, ZHAO Tong-chao, WANG Min, WANG Li-zhen, LI Jiang, ZHANG Chen-ping, ZHANG Zhi-yuan, ZHONG Lai-ping. TP53 truncating mutation as a predictive biomarker for induction chemotherapy in patients with locally advanced oral squamous cell carcinoma[J]. China Journal of Oral and Maxillofacial Surgery, 2018, 16(4): 322-327.

References

[1] Warnakulasuriya S.Global epidemiology of oral and oropharyngeal cancer[J]. Oral Oncol, 2009, 45(4-5): 309-316.
[2] Torre LA, Bray F, Siegel RL, et al.Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
[3] Gyawali B, Shimokata T, Honda K, et al.Chemotherapy in locally advanced head and neck squamous cell carcinoma[J]. Cancer Treat Rev, 2016, 44(1):10-16.
[4] Paccagnella A, Mastromauro C, D'Amanzo P, et al. Induction chemotherapy before chemoradiotherapy in locally advanced head and neck cancer: the future?[J]. Oncologist, 2010, 15(Suppl 3):8-12.
[5] Busch CJ, Tribius S, Schafhausen P, et al.The current role of systemic chemotherapy in the primary treatment of head and neck cancer[J]. Cancer Treat Rev, 2015, 41(3): 217-221.
[6] Haddad R, O'Neill A, Rabinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial[J]. Lancet Oncol, 2013, 14(3): 257-264.
[7] Zhong LP, Zhang CP, Ren GX, et al.Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma[J]. J Clin Oncol, 2013, 31(6): 744-751.
[8] Cohen EE, Karrison TG, Kocherginsky M, et al.Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer[J]. J Clin Oncol, 2014, 32(25): 2735-2743.
[9] Steels E, Paesmans M, Berghmans T, et al.Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis[J]. Eur Respir J, 2001, 18(4): 705-719.
[10] Weller M, Felsberg J, Hartmann C, et al.Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the german glioma network[J]. J Clin Oncol, 2009, 27(34): 5743-5750.
[11] Gonzalez D, Martinez P, Wade R, et al.Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial[J]. J Clin Oncol, 2011, 29(16): 2223-2229.
[12] Petitjean A, Mathe E, Kato S, et al.Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the Iarc TP53 database[J]. Hum Mutat, 2007, 28(6): 622-629.
[13] Li W, Lai B, Yang X, et al.A truncated p53 in human lung cancer cells as a critical determinant of proliferation and invasiveness[J]. Tumour Biol, 2017, 39(6): 1010428317703824.
[14] Cerami E, Gao J, Dogrusoz U, et al.The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data[J]. Cancer Discov, 2012, 2(5): 401-404.
[15] Gao J, Aksoy BA, Dogrusoz U, et al.Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal[J]. Sci Signal, 2013, 6(269): 11-44.
[16] Pignon JP, le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 Patients[J]. Radiother Oncol, 2009, 92(1): 4-14.
[17] Ma J, Liu Y, Yang X, et al.Induction chemotherapy in patients with resectable head and neck squamous cell carcinoma: a meta-analysis[J]. World J Surg Oncol, 2013, 11(1):67-73.
[18] Pointreau Y, Atean I, Fayette J, et al.Induction chemotherapy in head and neck cancer: a new paradigm[J].Anticancer Drugs, 2011, 22(7):613-620.
[19] Zhu DW, Liu Y, Yang X, et al.Low Annexin A1 expression predicts benefit from induction chemotherapy in oral cancer patients with moderate or poor pathologic differentiation grade[J]. BMC Cancer, 2013, 13(1):301-310.
[20] Ma J, Tang X, Sun WW, et al.Mutant GDF15 presents a poor prognostic outcome for patients with oral squamous cell carcinoma[J]. Oncotarget, 2016, 7(2): 2113-2122.
[21] Omura G, Ando M, Ebihara Y, et al.The prognostic value of TP53 mutations in hypopharyngeal squamous cell carcinoma[J]. BMC Cancer, 2017, 17(1): 898-907.
[22] Lindenbergh-van der Plas M, Brakenhoff RH, Kuik DJ, et al. Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma[J]. Clin Cancer Res, 2011, 17(11): 3733-3741.
[23] Fernandez-Cuesta L, Oakman C, Falagan-Lotsch P, et al.Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III Trial[J]. Breast Cancer Res, 2012, 14(3): 1-13.
[24] Tandon S, Tudur-Smith C, Riley RD, et al.A systematic review of p53 as a prognostic factor of survival in squamous cell carcinoma of the four main anatomical subsites of the head and neck[J]. Cancer Epidemiol Biomarkers Prev, 2010, 19(2): 574-587.
[25] Eicheler W, Zips D, Dorfler A, et al.Splicing Mutations in TP53 in human squamous cell carcinoma lines influence immunohistochemical detection[J]. J Histochem Cytochem, 2002, 50(2): 197-204.
[26] Scheel A, Bellile E, McHugh JB, et al. Classification of TP53 mutations and HPV predict survival in advanced larynx cancer[J]. Laryngoscope, 2016, 126(9): E292-E299.